58 results about "Acid molecule" patented technology

The invention discloses a lipid compound for delivering a therapeutic agent as well as a preparation method and application of the lipid compound, and particularly discloses a compound shown in a formula I or pharmaceutically acceptable salt, stereoisomer, tautomer, solvate, chelate, non-covalent complex or precursor of the compound, the ionizable lipid compound can effectively deliver nucleic acid molecules, small molecule compounds and other drugs, and through comparison, the lipid nanoparticles are good in particle size distribution and high in encapsulation efficiency, the delivery effect can be obviously better than that of contrast lipid nanoparticles, and the requirement of in-vivo delivery can be met. (I)

The invention discloses synthesis of 5-nucleotide phosphorodithioamide and application of the 5-nucleotide phosphorodithioamide in oligonucleotide. The oligonucleotide modified by the phosphorodithioamide comprises nucleotide structural units shown in a formula I or a formula II,..., the formula I,..., the formula II. According to the invention, through specific limitation of the structure of a nucleotide dithiophosphoramide monomer, the prepared oligonucleotide comprises a 5-nucleotide dithiophosphoramide structural unit. Compared with a traditional oligonucleotide molecule, the oligonucleotide molecule modified by nucleotide dithiophosphoramide shows better enzymatic degradation resistance and pharmaceutical stability. In addition, the binding performance between the modified oligonucleotide molecules and environmental ions can be improved through nucleotide dithiophosphamide modification, and a novel chemical modification strategy is provided for research, development and application of oligonucleotide drugs.

This tin alloy plating solution comprises: (A) a soluble salt that contains at least a stannous salt; (B) a soluble salt of a metal that is nobler than tin; (C) a leveling agent that is composed of an alkanesulfonic acid which contains 9-18 carbon atoms in each molecule or a salt thereof; (D) a free acid; (E) a nonionic surfactant that contains one or more phenyl groups in each molecule; and (F) an EO / PO block polymer that has an EO group at an end. The EO ratio in the EO / PO block polymer is within the range of 20 mol% to 50 mol% inclusive, and the molecular weight of the EO / PO block polymer is within the range of 1,500 to 3,500 inclusive.

This invention discloses a closed-loop acid-base recovery system and method for the resource recovery of weak organic acid salt wastewater. The front-end neutralization unit neutralizes fresh organic acid wastewater with alkali solution to generate a weak organic acid salt solution to be treated, which is then fed into a diffusion dialysis unit. The diffusion dialysis unit is divided into a diffusion liquid channel and a receiving liquid channel by a diffusion dialysis anion exchange membrane, achieving pre-enrichment of organic acid ions through concentration difference. The bipolar membrane electrodialysis unit, driven by a DC electric field, breaks down the weak organic acid salt into organic acid and alkali solution. The inlet of the acid chamber is connected to the diffusion liquid outlet of the diffusion dialysis unit, and all the produced dilute organic acid solution is transported to the diffusion dialysis unit as an acid receiving liquid for recycling. All the regenerated alkali solution produced in the alkali chamber is transported to the front-end neutralization unit for recycling. The receiving liquid outlet of the diffusion dialysis unit is connected to an acid product collection unit. This invention fundamentally inhibits the back diffusion of weak acid molecules, achieving efficient recovery of organic acids and recycling of alkali solution.

The present invention relates to a nucleic acid conjugate and methods of making and using the same, comprising: a first nucleic acid molecule, a second nucleic acid molecule, and a linker, the first nucleic acid molecule being linked to the second nucleic acid molecule by the linker, the linker linking the first nucleic acid molecule and the second nucleic acid molecule by a phosphodiester (p) or phosphorothioate (s) linkage, the linker being selected from the structures shown in Formula (I):

The invention relates to the technical field of biological medicine, and particularly discloses synthesis and application of oligonucleotide with threose nucleic acid 3-oxygen at the tail end indirectly connected with thiophosphoric acid. The chemical modification strategy comprises the following steps: O < 3->-oxygen of threose nucleic acid is connected with thiophosphoric acid through a spacer group, and O < 2->-hydroxyl is combined with a nucleotide monomer of phosphoramidite; carrying out solid-phase synthesis on the threose nucleic acid O2 '-phosphoramidite monomer to construct an oligonucleotide molecule; the oxygen of the threose nucleic acid at the terminal of the oligonucleotide is linked to the thiophosphoric acid through a spacer group, and since the type of phosphonic acid does not belong to a substrate of phosphatase, the modified oligonucleotide can resist exonuclease degradation and improve its in vivo biological activity.

The present invention relates generally to the field of molecular biology. More particularly, it concerns methods and compositions for detecting, evaluating, and / or mapping 5-hydroxymethyl-modified cytosine bases within a nucleic acid molecule.

The application discloses a reversible single-molecule switch based on local cation regulation and belongs to the technical field of molecular electronics. The application is based on the crack junction technology of an electrochemical scanning tunneling microscope. The distribution of local cations in an interface double electric layer is changed by controlling an electric potential, so that the state of a carboxylic acid molecule is influenced. The contact action of the carboxylic acid molecule and a gold needle tip is adjusted, and a single-molecule switch is realized. The electric potential is-0.5-0V. The application proves the influence of local cations in an electrochemical interface on carboxyl molecules, and opens up a new way for realizing the practical application of a reversible single-molecule switch through a gate electrode.

The present invention relates to a method for determining the sequence of a nucleic acid molecule. In particular, the present invention provides: i. a nucleic acid molecule comprising a 5' region and a 3' region, wherein the 5' region and the 3' region are covalently linked by a nucleotide sequence to which a primer can bind, and the base recognition in one of the 5' region or the 3' region and the base recognition in the other region together independently provide information regarding the base recognition at the corresponding locus in the original nucleic acid molecule, and the molecule further comprises: - one adapter at the 5' end of the molecule; - one adapter at the 3' end of the molecule; ii. sequencing the molecule provided in step (i) using at least two different primers, e.g., at least three different primers, preferably at least four different primers, wherein at least two different primers, e.g., at least three different primers, preferably at least four different primers, bind to at least three different regions, preferably at least four different regions in the nucleic acid molecule provided in (i): 1. At least one of the primers binds at least partially to at least a portion of the adapter at the 5' end of the molecule, thereby sequencing at least a portion of the 5' region of the nucleic acid molecule provided in (i); 2. The present invention provides a method comprising: 3. At least one of the primers at least partially binds to a region of a nucleotide sequence covalently linking the 5' and 3' regions of the nucleic acid molecule provided in (i), thereby enabling sequencing of at least a portion of the 3' region of the nucleic acid molecule provided in (i); 4. At least one of the primers at least partially binds to at least a portion of the adapter at the 3' end of the molecule, thereby enabling sequencing of at least a portion of the 3' region of the nucleic acid molecule provided in (i); and / or 5. At least one of the primers at least partially binds to a region of a nucleotide sequence covalently linking the 5' and 3' regions of the nucleic acid molecule provided in (i), thereby enabling sequencing of at least a portion of the 5' region of the nucleic acid molecule provided in (i).

The application discloses a kind of nanometer thickness square acid MOF film and preparation method thereof, and preparation method includes: preparation cationic surfactant, square acid, sodium hydroxide, metal salt is dissolved in water respectively and is matched into 1mg / mL solution;Square acid MOF Langmuir film is assembled using Langmuir film instrument, and square acid MOF film is transferred to solid substrate using Langmuir-Blogget method, to obtain nanometer thickness square acid MOF film;The application is induced by cationic surfactant to interface aggregation of water-soluble negative square acid molecule, interface pressure is reasonably controlled using Langmuir film preparation technology, adjust the distance between surfactant and interface charge density, then control the interface density of square acid ligand molecule and film thickness induced by it, prepare film thickness 2nm, size is centimeter level, defectless MOF film material.

A method for processing polynucleic acids is described, comprising: a) providing a solid support containing ligands, wherein at least a portion of the ligands contain a cyclic amine group having more than six ring members; exposing the solid support to polynucleic acid molecules in a buffer having a pH less than 5.5 to bind at least a portion of the polynucleic acid molecules to the ligands; exposing the solid support having the bound polynucleic acid molecules to a pH greater than 6 to release a portion of the bound polynucleic acid molecules from the ligands of the solid support, optionally retaining a portion of the polynucleic acid molecules bound to the solid support; and utilizing the released portion of the bound polynucleic acid molecules and / or the retained portion of the polynucleic acid molecules bound to the solid support, or a suspension thereof. A solid support containing ligands bound to a solid support (e.g., magnetic beads), wherein at least a portion of the ligands contain a cyclic amine group having more than six ring members, and a kit containing such a solid support are also described.

This invention belongs to the field of novel glycoconjugates and provides a method for preparing a sialic acid-gold nanomaterial composite. The method includes the following steps: S1: synthesizing a sialic acid ligand functional molecule; S2: synthesizing a PC molecule; S3: replacing the stabilizing molecule on the surface of the gold nanomaterial with a modified molecule under the action of a promoter to obtain a surface-modified material intermediate; S4: activating the surface carboxyl groups of the surface-modified material intermediate, reacting it with the PC molecule and the sialic acid ligand functional molecule, and connecting them through amide bonds. This invention provides a method for creating a sialic acid-gold nanocomposite material with a novel surface structure. The sialic acid molecule is obtained by modifying the structure of natural sialic acid molecules and can specifically recognize and bind to the SARS-CoV-2 S protein. The superhydrophilic properties of the PC group are utilized to reduce non-specific interference of complex environments on the material, while maintaining the biological effects of the sialic acid-gold nanocomposite material.

The application discloses a high-stability small-particle-size nucleic acid-gold nanocomposite and a synthesis method thereof, and belongs to the technical field of functional nanomaterial preparation, and the synthesis method comprises the following steps: under the conditions of heating and stirring, a reducing agent solution is added into a boiling chloroauric acid aqueous solution in batches, a solution of a functional nucleic acid molecule with a PolyA sequence at the terminal is added after boiling again, an acetic acid solution is added when the color of the reaction system is changed from light pink or light purple to dark, and the high-stability small-particle-size nucleic acid-gold nanocomposite is prepared after the reaction is completed; the application provides a brand-new "one-pot" synthesis strategy, discards complicated multi-step separation operation, realizes the synthesis of gold nanoparticles and the surface nucleic acid functionalization of the gold nanoparticles in one step in the same reaction system, the preparation process is simple, the product is uniform in particle size, good in dispersity, free from a plasmon resonance absorption peak, and has excellent long-term storage stability without depending on any exogenous polymer protective agent.

To provide methods and systems for analyzing nucleic acid molecules.SOLUTION: Processes and materials to detect cancer from a biopsy are described. In some cases, cell-free nucleic acids can be sequenced, and the sequencing result can be utilized to detect sequences derived from a neoplasm. Detection of somatic variants occurring in phase can indicate the presence of cancer in a diagnostic scan and a clinical intervention can be performed. The present disclosure provides methods and systems for analyzing cell-free nucleic acids (e.g., cfDNA, cfRNA) from a subject. Methods and systems of the present disclosure can utilize sequencing results derived from the subject to detect cancer-derived nucleic acids (e.g., ctDNA, ctRNA) for, e.g., disease diagnosis, disease monitoring, or determining treatments for the subject.SELECTED DRAWING: None

The invention discloses a multiple nested framework material MNF-2 constructed based on a dynamic B <-N bond and a preparation method of the multiple nested framework material MNF-2. The material MNF-2 is prepared from monomer molecules, 1, 4-phenylenediboronic acid and 4-chlorocatechol as raw materials; wherein 1, 4-benzene diboronic acid and 4-chlorocatechol are dehydrated to generate a boric acid ester structure, and B atoms of boric acid ester are combined with N atoms in monomer molecules to form B <-N coordinate bonds. A monomer molecule 4, 4, 8, 8, 12, 12-hexamethyl-2, 6, 10-tri (4-pyridyl)-8, 12-dihydro-4H-benzo [9, 1] quinolizino [3, 4, 5, 6, 7-defg] anthracene (monomer molecule M1 for short) is synthesized firstly, the monomer molecule M1 and a lewis acid molecule (4-chlorocatechol) are subjected to a one-pot method through a B <-N bond in a solution to effectively generate an MNF material, and a two-dimensional lamellar structure is formed. The lamellar material has excellent mechanical properties. The acting force range of the two-dimensional MNF material is further widened, and a new strategy is provided for preparation of the two-dimensional MNF material.

Disclosed herein are modifications of polynucleic acid molecules such as inhibitory polynucleic acid molecules and pharmaceutical compositions comprising modified polynucleic acid molecules. Further, provided herein are methods for utilization of modified polynucleic acid molecules as well as methods for suppressing an expression of gene targeted by the modified polynucleic acid molecules.

The invention discloses synthesis of 3 '-amido-5-nucleotide phosphamide and application of the 3'-amido-5-nucleotide phosphamide in oligonucleotide. The phosphamide modified oligonucleotide comprises at least one of nucleotide structural units shown in a formula I, a formula II, a formula III or a formula IV,..., the formula I, the formula II, the formula III,..., the formula IV. Through specific limitation of a nucleotide phosphamide monomer structure, oligonucleotides are prepared by coupling according to a direction from 5 to 3. Compared with a traditional oligonucleotide molecule, the oligonucleotide molecule provided by the invention contains phosphamide modification and has more excellent effects on pharmaceutical parameters such as enzymatic degradation resistance, stability and the like, in addition, the phosphamide modification can improve the binding performance between the modified oligonucleotide molecule and environmental ions, and the stability of the oligonucleotide molecule is improved. A novel chemical modification strategy is provided for research, development and application of oligonucleotide drugs.

This invention relates to a heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity, its preparation method, and its application, belonging to the field of biomedical technology. The heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity comprises an AT-binding sequence and a -GlcNS(6S)-GlcA2S- or -GlcNS(6S)-IdoA2S- linker sequence, specifically heparin anticoagulant dodecanosaccharide 12I-2, heparin anticoagulant dodecanosaccharide 12G-1, or heparin anticoagulant dodecanosaccharide 12G-2. This invention also provides methods for preparing heparin anticoagulant dodecanosaccharides 12I-2, 12G-1, and 12G-2, and their applications in the preparation of safe and effective anticoagulant and antithrombotic drugs. The heparin anticoagulant oligosaccharide designed in this invention is a specific dodecanoic acid molecule. By optimizing its sugar chain length, key structural domains and spatial conformation, its ability to form pathogenic H / PF4 complexes with platelet factor 4 (PF4) is weakened to the greatest extent. In clinical anticoagulation applications, it has a significant safety advantage in reducing the incidence of HIT and related fatal thrombosis (HITT).

The application provides a functionalized biochar material, a preparation method and application thereof, and relates to the technical field of biochar materials, and particularly relates to a functionalized biochar material, a preparation method and application thereof. The functionalized biochar material comprises a biochar base body and a functional interface layer constructed on the surface of the biochar base body; the functional interface layer comprises complexation or coordination active sites fixed on functional groups on the surface of the biochar; the complexation or coordination active sites are composed of polycarboxyl chelating groups covalently fixed on the surface of the biochar and metal ions, metal oxides or metal hydroxides, and can occur competitive complexation or coordination reconstruction under the action of polycarboxyl organic acid molecules secreted by plant roots, so as to realize reversible regulation of the interface chemical state. The functionalized biochar material can occur multiple interface coordination reconstructions along with the change of the concentration and types of rhizosphere organic acids of plants, so as to realize continuous regulation of the fixed, migrated and released states of nutrients or functional components, and make the regulation behavior more easily matched with the space-time distribution of rhizosphere organic acids.

The invention discloses a polyacid flow battery electrolyte and a preparation method and application thereof, and belongs to the technical field of electrochemical energy storage. The method comprises the following steps: sequentially adding a supporting electrolyte, an electrolyte and an additive into a solvent, stirring until the supporting electrolyte, the electrolyte and the additive are completely dissolved, adjusting the pH value to 1.90-2.10, and introducing a protective atmosphere for deoxidation treatment to obtain the polyacid flow battery electrolyte, and the additive is SnCl2. 2H2O, or SnCl2. 2H2O and histidine. Sn < 2 + > in SnCl2. 2H2O is deposited on the surface of the carbon felt electrode to form a nano film or particles of metallic tin, and the adsorption of the Sn surface to H < + > is weak, so that the hydrogen evolution reaction is effectively inhibited; sn < 2 + > is preferentially reduced on the surface of the carbon felt negative electrode, has good catalytic activity on the reduction reaction of polyacid molecules, reduces the reaction activation energy and improves the conversion rate of the polyacid molecules. Imidazolyl, carboxyl and amino in histidine molecules can effectively stabilize the pH value and the reduced phosphotungstic acid structure. The electrode interface property is obviously changed, the hydrogen evolution reaction is inhibited, and the coulombic efficiency, the voltage efficiency and the energy efficiency are improved.

Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions, and methods and uses thereof.

The invention relates to the technical field of biological medicine, and particularly discloses synthesis of 5-terminal phosphonic acid nucleotide and application of the 5-terminal phosphonic acid nucleotide in oligonucleotide. The chemical modification strategy comprises the following steps: preparing a 5 '-phosphonite modified nucleotide phosphoramidite monomer and a 5'-phosphonite modified nucleotide phosphoramidite monomer; the modified nucleotide phosphoramidite is used for preparing a target oligonucleotide molecule, carbon-phosphonic acid C-PO32-chemical bond connection is constructed at the 5-terminal of the target oligonucleotide molecule, a 5 '-terminal phosphonic acid structure in a non-natural form is formed and does not belong to a natural substrate of phosphatase, the modified oligonucleotide can resist nuclease degradation, the affinity of the oligonucleotide with specific protein can be improved, and the oligonucleotide can be used for preparing the target oligonucleotide. And the in-vivo biological activity of the siRNA is improved.

Disclosed herein are polynucleic acid molecules that can be utilized for suppressing the expression of inhibin subunit beta E (INHBE). Also, described herein are pharmaceutical compositions comprising polynucleic acid molecules targeting inhibin subunit beta E (INHBE) mRNA. Further, provided herein are methods for suppressing the expression of inhibin subunit beta E (INHBE) by utilizing the polynucleic acid molecules described herein.

The invention discloses synthesis of 3 '-amido-5-nucleotide thiophosphoramide and application of the 3'-amido-5-nucleotide thiophosphoramide in oligonucleotide. The thiophosphoramide modified oligonucleotide comprises at least one of nucleotide structural units shown in a formula I, a formula II, a formula III or a formula IV,..., the formula I, the formula II, the formula III,..., the formula IV. Through specific limitation of a nucleotide thiophosphoramide monomer structure, oligonucleotides are prepared by coupling according to a direction from 5 to 3. The thiophosphoramide modification in the oligonucleotide molecule shows more excellent enzymatic degradation resistance and stability than the traditional oligonucleotide molecule. In addition, the thiophosphoramide modification can improve the binding performance between the modified oligonucleotide molecules and environmental ions, and a novel chemical modification strategy is provided for research, development and application of oligonucleotide drugs.

Provided herein are trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and at least two of the antigen binding sites specifically bind an interleukin-4 (IL-4) polypeptide and an interleukin-13 (IL-13) polypeptide, respectively. In some embodiments, the third antigen binding site specifically binds an OX40L polypeptide. The disclosure also relates to nucleic acid molecules, expression vectors, host cells, compositions (e.g., pharmaceutical compositions), methods of production, methods of use, and uses related thereto.

The present application relates to an aptamer nucleic acid molecule, a complex containing the aptamer nucleic acid molecules, a method of detecting intracellular or extracellular RNA, DNA or other target molecules, and a kit containing the aptamer. The aptamer of the present application is capable of specifically binding a kind of fluorophore micromolecules, and can significantly enhance fluorescence intensity under excitation light of appropriate wavelength.

Lipid nanoparticles for delivery of nucleic acid molecules, such as mRNA, are provided. Methods of making and using the same are also provided.